Bio Plus Co Ltd
Bio Plus Co Ltd is a South Korean pharmaceutical company that develops and commercializes biopharmaceutical products, primarily in the areas of oncology and autoimmune diseases.
Business. Bio Plus Co Ltd (099430.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Bio Plus Co Ltd (099430.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
### Capital Structure and Liquidity Bio Plus Co Ltd has a debt-to-equity ratio of 0.34, indicating a relatively conservative capital structure. However, the company's liquidity position is assessed as medium, with a current ratio of 0.84, suggesting that its current liabilities exceed its current assets. The company's cash and equivalents amount to 21,074.15 billion KRW, but this is insufficient to cover its long-term debt of 60,061.01 billion KRW, resulting in a net cash outflow.
### Profitability and Returns The company's return on equity (ROE) is 8.58%, and its return on assets (ROA) is 5.26%, both of which are in line with industry norms for pharmaceutical firms. The gross profit margin is 66.7%, and the operating margin is 16.4%, indicating strong profitability relative to its revenue base.
### Segments and Geographic Exposure Bio Plus Co Ltd operates primarily in the domestic South Korean market, with a significant portion of its revenue derived from the sale of biopharmaceutical products. The company has not disclosed specific geographic revenue breakdowns, but its operations are concentrated in the Asia-Pacific region.
### Growth Trajectory The company's revenue for the latest period is 90,896.01 billion KRW, with a net income of 15,001.44 billion KRW. While the company has shown consistent profitability, its free cash flow is negative at -23,868.34 billion KRW, primarily due to high capital expenditures of -47,928.11 billion KRW. Analysts have a positive outlook, with a mean recommendation of 1.00 (strong buy), and an expected EPS of 552.00 KRW, compared to the last actual EPS of 149.00 KRW.
### Risk Factors The company faces medium liquidity risk due to its current ratio of 0.84 and a negative net cash position after accounting for long-term debt. The risk of dilution is assessed as low, with no significant dilution potential in the near term. The company's capital expenditures are a key driver of its negative free cash flow, which could impact its ability to fund operations without external financing.
### Recent Events Recent filings and transcripts indicate that the company is focused on expanding its product pipeline and maintaining its competitive position in the biopharmaceutical market. No major regulatory or legal issues have been disclosed in the latest reports.
- Bio Plus Co Ltd maintains a strong profitability profile with an ROE of 8.58% and ROA of 5.26%.
- The company's liquidity position is medium, with a current ratio of 0.84 and a negative net cash position.
- Analysts have a strong buy recommendation, with a mean EPS estimate of 552.00 KRW.
- The company's free cash flow is negative due to high capital expenditures.
- The risk of dilution is low, and the company's capital structure is relatively conservative.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 552,00 |
| Revenue | —no estimate | —no estimate | 119,0B KRW |
| Operating income | —no estimate | —no estimate | 43,0B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Bio Plus Co Ltd Market data — financials · 2026-05-26
- Bio Plus Co Ltd Market data — analyst estimates · 2026-05-26
Ownership & reference
Leadership
- Hyun Kyu JungChairman of the Board, Chief Executive Officer